Christoph Koenen

A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes

Julio Rosenstock, Melanie J. Davies, Philip Home et al. · Diabetologia · 2008 · 446 citations · Full text

The usage of a simplified self‐titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes – results of the randomized, controlled PREDICTIVE™ 303 study

Luigi Meneghini, Christoph Koenen, Wayne Weng et al. · Diabetes Obesity and Metabolism · 2007 · 126 citations

Pharmacotherapy, Insulin Detemir Dose, Clinical Trials +17

Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study*

L. F. Meneghini, Kirsten Rosenberg, Christoph Koenen et al. · Diabetes Obesity and Metabolism · 2006 · 100 citations · Full text

Comparison of insulin detemir and insulin glargine in a basal—bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: A 52-week, multinational, randomized, open-label, parallel-group, Treat-to-Target noninferiority trial

Simon Heller, Christoph Koenen, Bruce W. Bode · Clinical Therapeutics · 2009 · 93 citations

Nutrition, Type 1, Diabetes Management +8

Safety and efficacy of insulin detemir in clinical practice: 14-week follow-up data from type 1 and type 2 diabetes patients in the PREDICTIVETM European cohort

Anne Dornhorst, H-J Lüddeke, Séamus Sreenan et al. · International Journal of Clinical Practice · 2007 · 83 citations